[Gliclazide in the non-insulin-dependent diabetic patient in geriatrics]

In the present open clinical pilot study of 12 months duration we tested the metabolic and hemato-biological efficacy as well as the clinical tolerance of the oral antidiabetic agent gliclazide, a second-generation sulfonylurea derivate, on a group of 20 hospitalized geriatric patients (mean age 80.5 +/- 10.2 years). Gliclazide was proven to be a reliable blood-sugar lowering agent with a generally good subjective tolerance. There were no undesired side-effects on the renal, hepatic and hematopoietic systems.